Plaque Psoriasis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2025-09-26
Clinical Trial Update: Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity
This Clinical Trial Update describes a Canadian real-world evidence study evaluating brodalumab for plaque psoriasis, aimed at understanding…
CLINICAL_TRIALS research · 2025-09-25
Clinical Trial Update: A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 pediatric trial to evaluate the drug levels, efficacy, and safety of deucravacitinib in children with moderate-to-severe plaque psor…
CLINICAL_TRIALS trial_result · 2025-09-24
Clinical Trial Update: A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
A completed study evaluated treatment satisfaction, patient-reported outcomes, effectiveness, and safety of Calcipotriene/Betamethone Diprop…
FDA approval · 2025-09-17
FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental BLA for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited. The action concerns regulatory approval rel…
CLINICAL_TRIALS trial_result · 2025-09-12
Clinical Trial Update: Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
A Phase 3 trial comparing the efficacy and safety of Bmab 1200 versus Stelara (ustekinumab) in adults with moderate-to-severe chronic plaque…
Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
CLINICAL_TRIALS trial_result · 2025-09-12
Clinical Trial Update: Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis [Phase 3]
Phase 3 study of guselkumab in skin of color participants with moderate-to-severe plaque psoriasis and/or scalp psoriasis has completed.
CLINICAL_TRIALS trial_result · 2025-09-12
Clinical Trial Update: A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis [Phase 2]
The document reports the completion of a long-term extension Phase 2 trial evaluating Janssen's investigational therapy JNJ-77242113 in adul…
CLINICAL_TRIALS trial_result · 2025-09-12
Clinical Trial Update: A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis [Phase 2]
The document provides an update that a Phase 2 study of LY4100511 (DC-853) in adults with moderate-to-severe plaque psoriasis has been compl…
CLINICAL_TRIALS trial_result · 2025-09-12
Clinical Trial Update: Study to Assess the Reliability of PASI Scoring Using Digital-Based Images
A completed clinical trial evaluating whether PASI scoring for plaque psoriasis can be reliably performed using digital-based images. The st…
CLINICAL_TRIALS trial_result · 2025-09-10
Clinical Trial Update: A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting [Phase 4]
A Phase 4 trial evaluated the effect of Deucravacitinib on quality of life in participants with plaque psoriasis in a community setting; res…
CLINICAL_TRIALS research · 2025-09-10
Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis [Phase 1, Phase 2]
Chipscreen Biosciences is conducting a Phase 1/2 study to evaluate the efficacy and safety of CS32582 in adults with moderate to severe plaq…
CLINICAL_TRIALS research · 2025-09-10
Clinical Trial Update: Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis [Phase 3]
A Phase 3 comparative trial comparing CMAB015 with Secukinumab for moderate to severe plaque psoriasis is active but not recruiting.
CLINICAL_TRIALS research · 2025-09-05
Clinical Trial Update: A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of HSK47388 tablets in patients with moderate-to-severe plaque psoriasis; the stud…
FDA approval · 2025-09-03
FDA Approved: INFLECTRA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Inflectra (infliximab-dyyb) from Pfizer to update its labeling and/or indications, following…
EMA approval · 2025-08-27
EMA Authorised: Kyntheum (brodalumab) — LEO Pharma A/S
EMA authorised Kyntheum (brodalumab) by LEO Pharma A/S for psoriasis; decision date 27 August 2025.
CLINICAL_TRIALS research · 2025-08-27
Clinical Trial Update: A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis [Phase 4]
This update describes a Phase 4 safety and pharmacokinetics study of IDP-122 Lotion in pediatric participants with plaque psoriasis, current…
CLINICAL_TRIALS trial_result · 2025-08-22
Clinical Trial Update: A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India [Phase 4]
A Phase 4 study evaluating ixekizumab for adults with plaque psoriasis or psoriatic arthritis in India has completed, with results posted.
CLINICAL_TRIALS trial_result · 2025-08-17
Clinical Trial Update: IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment [Phase 3]
Phase 3 trial update for IBI112 in moderate-to-severe plaque psoriasis, involving randomized withdrawal and re-treatment; the study status i…
FDA approval · 2025-08-14
FDA Approved: OTULFI — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for OTULFI (ustekinumab-AAUZ) from Fresenius Kabi USA, LLC.
CLINICAL_TRIALS trial_result · 2025-08-13
Clinical Trial Update: Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]
This report covers the completion of a Phase 3 study evaluating the efficacy and safety of HLX03 in adults with moderate-to-severe plaque ps…
CLINICAL_TRIALS trial_result · 2025-08-12
Clinical Trial Update: Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 [Phase 3]
This update reports on adverse events and changes in disease activity in pediatric participants aged 6 to 17 with moderate-to-severe plaque …
CLINICAL_TRIALS research · 2025-08-11
Clinical Trial Update: New Topical Treatment in Plaque Psoriasis [NA]
A new topical treatment is being studied in a clinical trial for plaque psoriasis, which is currently not recruiting.
CLINICAL_TRIALS research · 2025-08-05
Clinical Trial Update: A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis [Phase 2]
A Phase 2 clinical study to evaluate the safety and pharmacokinetics of RSS0393 topical ointment in children and adolescents with plaque pso…
CLINICAL_TRIALS trial_result · 2025-07-30
Clinical Trial Update: An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating GNR-068, a ustekinumab biosimilar, versus Stelara for moderate-to-severe plaque psoriasis; study is active but not …
FDA approval · 2025-07-29
FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Sandoz Inc for the adalimumab biosimilar ADALIMUMAB-ADAZ, enabling its use with indications cons…